Techniclone Agrees to License Technology
- Share via
Techniclone Corp., a Tustin developer of cancer treatments, said Thursday that it has tentatively agreed to license one of its technologies to a San Ramon, Calif., company for about $8 million.
The price includes an upfront payment, certain future payments and a royalty.
Techniclone said in a press release that SuperGen Inc. will license its Vascular Targeting Agent technology, which is a therapeutic treatment designed specifically to destroy vascular tumors.
SuperGen said it believes the technology can deliver a wide range of cancer-fighting drugs.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
